Welcome to our dedicated page for Palvella Therapeutics SEC filings (Ticker: PVLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinicians aren’t the only ones parsing dense study tables: investors trying to locate R&D burn or pivotal-trial milestones inside Palvella Therapeutics’ SEC disclosures face the same hurdle. Whether you’re scanning the company’s QTORIN® platform updates or gauging cash runway before the next phase 3 read-out, every detail is hidden across multiple forms. Stock Titan turns that complexity into clarity by delivering Palvella Therapeutics SEC filings explained simply, complete with plain-language AI summaries minutes after each document hits EDGAR.
Type a natural question—“How do I read the Palvella Therapeutics annual report 10-K?” or “Where are Palvella Therapeutics insider trading Form 4 transactions?”—and our engine surfaces the answer. You’ll receive real-time alerts for Palvella Therapeutics Form 4 insider transactions real-time and concise takeaways from every Palvella Therapeutics quarterly earnings report 10-Q filing. Key filings are decoded so you can:
- Track pipeline progress via Palvella Therapeutics 8-K material events explained by AI
- Spot executive stock moves through Palvella Therapeutics executive stock transactions Form 4
- Review board pay inside the Palvella Therapeutics proxy statement executive compensation section
- Compare cash usage and trial spend with Palvella Therapeutics earnings report filing analysis
- Download the Palvella Therapeutics annual report 10-K simplified for quick reference
Behind every headline number, Stock Titan’s AI pinpoints what matters for a clinical-stage biotech: dilution risk from follow-on offerings, milestone-based licensing revenues, and the pace of enrollment for rare-disease studies. Understanding Palvella Therapeutics SEC documents with AI means you see how QTORIN® formulation costs translate into future margins and how insider sentiment aligns with pending data releases. Stop wading through technical jargon—view, search, and act on every disclosure the moment it is filed.
Palvella Therapeutics, Inc. reported a key clinical update for its dermatology program. On
Palvella also issued a press release, filed as Exhibit 99.2, announcing positive topline results from this ongoing Phase 2 study. Together, the call, slides, and press release highlight progress in the clinical development of QTORIN for this indication, giving investors more detail on how the program is advancing.
Palvella Therapeutics (PVLA) reported insider transactions by its Chief Operating Officer on a Form 4. On 11/19/2025, the officer exercised stock options to acquire 2,154 shares of common stock at $7.14 per share and 2,148 shares at $9.08 per share. The same day, the officer sold 1,500 shares at a weighted average price of $85.7183 and 2,802 shares at a weighted average price of $86.5053, leaving 0 shares of common stock directly owned after these transactions.
The filing shows remaining fully vested stock options covering 2,154 shares expiring on 10/29/2029 and 2,148 shares expiring on 10/14/2030, with post‑transaction option holdings of 23,705 and 23,628 options in those grants. All transactions were carried out under a Rule 10b5‑1 trading plan adopted on August 19, 2025.
Palvella Therapeutics (PVLA) reported third‑quarter 2025 results highlighting increased investment in late‑stage programs and a larger loss. Cash and cash equivalents were $63.6 million at September 30, 2025, down from $83.6 million at year‑end. Q3 operating expenses rose to $10.2 million, driven by research and development of QTORIN rapamycin and higher general and administrative costs. The company recorded a net loss of $11.3 million for Q3 2025 and $29.0 million year‑to‑date.
Palvella’s royalty agreement liability increased to $16.0 million, with non‑cash interest expense of $1.5 million in Q3. Net cash used in operating activities was $20.1 million for the nine months. Management states existing cash is sufficient to support operations for at least one year from the financial statement issuance date. Clinical progress continued: the Phase 3 SELVA trial completed enrollment with 51 patients, and the Phase 2 TOIVA trial completed enrollment with 16 patients. The company recognized $0.4 million of government grant income year‑to‑date related to SELVA and received $0.5 million in May and $0.6 million in October 2025. Shares outstanding were 11,836,490 as of November 7, 2025.
Palvella Therapeutics, Inc. furnished an update that it will announce its financial results for the quarter ended September 30, 2025 and hold an earnings call on November 11, 2025. The company attached its press release as Exhibit 99.1 and an earnings call slide presentation as Exhibit 99.2.
The materials are furnished under Items 2.02 and 7.01 and are not deemed “filed” for liability purposes under the Exchange Act, except as expressly incorporated by reference. Palvella’s common stock trades on the Nasdaq Capital Market under the symbol PVLA.
Palvella Therapeutics (PVLA)
An investor presentation was furnished as Exhibit 99.1 and a press release as Exhibit 99.2. The information was furnished under Item 7.01 and is not deemed filed under the Exchange Act.
Palvella Therapeutics disclosed on
The notice is procedural in form: it confirms the program expansion but does not provide clinical data, trial design, timelines, or cost information. The filing is signed by the company’s Chief Financial Officer, indicating formal corporate disclosure rather than new regulatory approvals or completed clinical results.
Palvella Therapeutics, Inc. furnished a Regulation FD disclosure on
Palvella Therapeutics, Inc. (PVLA) disclosed a Schedule 13G/A reporting that Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and Srinivas Akkaraju together beneficially own 339,743 shares of common stock, representing 3.1% of the class based on 11,055,665 shares outstanding as of May 9, 2025. The filing states Samsara LP directly holds the shares, Samsara GP is the general partner and Dr. Akkaraju is a managing member, and that the holdings were not acquired to change or influence control of the issuer.
The filing is dated for the reporting event as of June 30, 2025 and signatures show execution on August 14, 2025. The reporting address is c/o Samsara BioCapital, LLC, Palo Alto, CA.
Frazier Life Sciences and affiliated funds report their holdings in Palvella Therapeutics, Inc. common stock. Frazier Life Sciences Public Fund, L.P. (FLSPF) directly holds 545,504 shares, which the filing states represents 4.9% of the 11,055,665 shares of common stock used for the percentage calculation. Other Frazier vehicles reported include holdings of 160,856, 7,517, 4,730 and 3,793 shares, with sole voting and dispositive power reported as 0 and shared power reported where indicated.
The filing corrects prior attributions by stating members of certain investment committees are not attributed beneficial ownership of fund-held securities. It also discloses prefunded warrants: FLSPF holds warrants to purchase 937,965 shares, FLSPOF 276,766, FLS X 5,641 and FLS XI 5,886, each subject to exercise limits preventing the holder from exceeding 4.99% beneficial ownership after exercise. The statement clarifies ownership, voting and dispositive arrangements among the reporting persons.
Palvella Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on topical QTORIN rapamycin for rare genetic skin diseases. At June 30, 2025 the company held $70.4 million in cash and cash equivalents, total assets of $73.7 million and an accumulated deficit of $111.4 million. For the six months ended June 30, 2025 Palvella reported a net loss of $17.7 million driven by total operating expenses of $17.1 million (R&D and G&A).
The company completed a reverse merger and related PIPE financing that provided substantial capital; management states existing cash is sufficient to support operations through at least one year from issuance of these statements assuming no additional fundraising. Key balance sheet items include a $14.5 million royalty agreement liability and Level 3 derivative liabilities for the royalty agreement and contingent value rights totaling $3.8 million. Clinical progress includes completion of enrollment in the Phase 3 SELVA trial (51 subjects), dosing in the Phase 2 TOIVA trial, receipt of an initial $0.5 million FDA grant, and a newly granted U.S. patent for anhydrous rapamycin formulations.
FAQ
What is the current stock price of Palvella Therapeutics (PVLA)?
What is the market cap of Palvella Therapeutics (PVLA)?
